metformin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics, phenformin derivatives 1725 657-24-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • metformin
  • metformin hydrochloride
  • glucophage
  • LA-6023
  • LA 6023
  • N,N-dimethylguanylguanidine
  • metformin HCl
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
  • Molecular weight: 129.17
  • Formula: C4H11N5
  • CLOGP: -1.43
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 88.99
  • ALOGS: -1.97
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 99 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 387.10 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 52 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.64 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
March 3, 1995 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 11686.99 9.94 5343 314268 28566 46337885
Acute kidney injury 2863.36 9.94 5487 314124 230368 46136083
Hypoglycaemia 2714.51 9.94 2538 317073 51811 46314640
Blood glucose increased 2196.49 9.94 2584 317027 69429 46297022
Diabetic ketoacidosis 2188.69 9.94 1431 318180 16779 46349672
Metabolic acidosis 1811.55 9.94 1746 317865 37034 46329417
Glycosylated haemoglobin increased 1020.74 9.94 734 318877 10142 46356309
Ketoacidosis 1002.95 9.94 506 319105 3449 46363002
Diabetes mellitus inadequate control 987.30 9.94 778 318833 12436 46354015
Hyperkalaemia 806.43 9.94 1331 318280 49378 46317073
Hyperglycaemia 705.21 9.94 1026 318585 34045 46332406
Euglycaemic diabetic ketoacidosis 653.07 9.94 305 319306 1711 46364740
Rheumatoid arthritis 580.51 9.94 476 319135 239739 46126712
Hypoglycaemic coma 476.46 9.94 267 319344 2307 46364144
Pancreatitis 463.76 9.94 963 318648 42664 46323787
Blood glucose decreased 455.02 9.94 603 319008 18289 46348162
Pancreatitis acute 414.37 9.94 667 318944 24205 46342246
Myocardial infarction 389.41 9.94 1508 318103 96020 46270431
Drug ineffective 366.45 9.94 2933 316678 674905 45691546
Hyperlactacidaemia 351.90 9.94 208 319403 2007 46364444
Pemphigoid 347.36 9.94 298 319313 5393 46361058
Anuria 344.15 9.94 408 319203 11023 46355428
Shock 343.83 9.94 571 319040 21274 46345177
Diabetes mellitus 333.65 9.94 922 318689 49143 46317308
Blood glucose abnormal 319.90 9.94 305 319306 6367 46360084
Renal failure 294.90 9.94 1546 318065 112048 46254403
Diarrhoea 286.83 9.94 5395 314216 554207 45812244
Diabetic metabolic decompensation 284.11 9.94 146 319465 1039 46365412
Systemic lupus erythematosus 274.23 9.94 56 319555 65124 46301327
Cardiac failure congestive 264.30 9.94 1286 318325 90464 46275987
Coronary artery disease 258.82 9.94 655 318956 33097 46333354
Treatment failure 256.50 9.94 160 319451 92927 46273524
Drug intolerance 230.77 9.94 408 319203 146641 46219810
Vomiting 222.80 9.94 4340 315271 448454 45917997
Haemodialysis 217.01 9.94 291 319320 8926 46357525
Pancreatic carcinoma 214.04 9.94 244 319367 6313 46360138
Synovitis 212.72 9.94 76 319535 60999 46305452
Dehydration 201.37 9.94 1818 317793 157722 46208729
Hypothermia 200.54 9.94 325 319286 11858 46354593
Drug level increased 199.32 9.94 410 319201 18031 46348420
Pemphigus 188.16 9.94 40 319571 45234 46321217
Off label use 185.59 9.94 1685 317926 378156 45988295
Febrile neutropenia 184.10 9.94 226 319385 94401 46272050
Contraindicated product administered 179.94 9.94 169 319442 79778 46286673
Blood glucose fluctuation 179.06 9.94 179 319432 3967 46362484
Pyrexia 175.75 9.94 1535 318076 347267 46019184
Vitamin B12 deficiency 174.08 9.94 173 319438 3806 46362645
Continuous haemodiafiltration 164.26 9.94 97 319514 934 46365517
Drug hypersensitivity 157.57 9.94 1000 318611 242825 46123626
Death 157.56 9.94 1503 318108 334045 46032406
Infusion related reaction 154.95 9.94 285 319326 100923 46265528
Neutropenia 152.31 9.94 488 319123 142716 46223735
Glossodynia 151.50 9.94 57 319554 44316 46322135
Hand deformity 151.15 9.94 27 319584 34547 46331904
Rash 150.86 9.94 1637 317974 354875 46011576
Type 2 diabetes mellitus 148.50 9.94 382 319229 19493 46346958
Joint swelling 145.70 9.94 613 318998 165460 46200991
Blood lactic acid increased 143.07 9.94 185 319426 5472 46360979
Weight decreased 140.21 9.94 2123 317488 208726 46157725
Pain 133.82 9.94 2380 317231 474568 45891883
Infection 130.66 9.94 472 319139 133120 46233331
Rheumatoid factor positive 125.57 9.94 3 319608 20458 46345993
Cerebrovascular accident 119.59 9.94 1136 318475 99903 46266548
Musculoskeletal stiffness 119.44 9.94 313 319298 97680 46268771
Arthropathy 116.36 9.94 254 319357 84446 46282005
Alopecia 115.98 9.94 645 318966 161769 46204682
Rhabdomyolysis 113.18 9.94 577 319034 41332 46325119
Product residue present 111.01 9.94 135 319476 3747 46362704
Pneumonia 106.94 9.94 1873 317738 374447 45992004
Acidosis 101.94 9.94 232 319379 10942 46355509
Blood bicarbonate decreased 100.39 9.94 111 319500 2774 46363677
Tachypnoea 93.28 9.94 262 319349 14089 46352362
Hypomagnesaemia 92.25 9.94 348 319263 21862 46344589
Pancreatic carcinoma metastatic 91.40 9.94 97 319514 2311 46364140
Hepatic steatosis 91.15 9.94 366 319245 23676 46342775
Ketosis 89.70 9.94 50 319561 427 46366024
Injection site nodule 89.59 9.94 113 319498 3258 46363193
Blood creatinine increased 88.39 9.94 855 318756 75548 46290903
Fatigue 86.99 9.94 3350 316261 605347 45761104
Drug interaction 86.64 9.94 1908 317703 201186 46165265
Swelling 86.41 9.94 499 319112 124012 46242439
Therapeutic product effect decreased 84.64 9.94 286 319325 82315 46284136
Urine ketone body present 84.36 9.94 88 319523 2054 46364397
Hypersensitivity 82.99 9.94 645 318966 149676 46216775
Toxicity to various agents 82.73 9.94 1965 317646 209801 46156650
Polyuria 82.54 9.94 164 319447 7031 46359420
C-reactive protein abnormal 82.06 9.94 22 319589 21248 46345203
Microalbuminuria 79.87 9.94 41 319570 291 46366160
Arthralgia 79.29 9.94 1896 317715 362707 46003744
White blood cell count decreased 78.83 9.94 448 319163 111783 46254668
Seizure 75.64 9.94 512 319099 122542 46243909
Intentional overdose 75.23 9.94 727 318884 64217 46302234
Sinusitis 72.47 9.94 555 319056 129213 46237238
Disease progression 72.20 9.94 350 319261 90950 46275501
Diabetic neuropathy 72.00 9.94 108 319503 3681 46362770
Acetonaemia 70.77 9.94 25 319586 56 46366395
Acute myocardial infarction 70.38 9.94 416 319195 31508 46334943
Vasoplegia syndrome 70.37 9.94 59 319552 1033 46365418
Insulin resistance 69.90 9.94 49 319562 648 46365803
Cytomegalovirus infection 69.56 9.94 19 319592 18125 46348326
Postprandial hypoglycaemia 69.25 9.94 23 319588 39 46366412
Coma acidotic 68.64 9.94 28 319583 106 46366345
Leukopenia 68.41 9.94 239 319372 68104 46298347
Neurologic neglect syndrome 65.96 9.94 47 319564 639 46365812
Ketonuria 65.58 9.94 38 319573 352 46366099
Hypoglycaemic encephalopathy 65.58 9.94 34 319577 247 46366204
Thrombocytopenia 64.88 9.94 554 319057 126027 46240424
Migraine 64.77 9.94 253 319358 69773 46296678
Pericarditis 64.67 9.94 42 319569 23885 46342566
Glycosylated haemoglobin decreased 63.93 9.94 41 319570 463 46365988
Anion gap increased 63.70 9.94 64 319547 1427 46365024
Carotid artery thrombosis 63.34 9.94 47 319564 683 46365768
Product use issue 63.15 9.94 384 319227 94260 46272191
Coronary artery bypass 61.89 9.94 80 319531 2365 46364086
Lipase increased 61.84 9.94 163 319448 8440 46358011
Blood ketone body increased 60 9.94 32 319579 248 46366203
Plasma cell myeloma 59.73 9.94 135 319476 44343 46322108
Nausea 59.03 9.94 5465 314146 681989 45684462
Renal impairment 59.02 9.94 773 318838 73599 46292852
Drug abuse 58.07 9.94 230 319381 63178 46303273
Adenocarcinoma pancreas 58.02 9.94 54 319557 1092 46365359
Amylase increased 56.21 9.94 119 319492 5340 46361111
Angioedema 56.15 9.94 461 319150 38881 46327570
Wound 55.80 9.94 132 319479 42670 46323781
Device expulsion 55.43 9.94 64 319547 27478 46338973
Bone marrow failure 54.42 9.94 74 319537 29595 46336856
Neutrophil count decreased 54.19 9.94 137 319474 43289 46323162
Stomatitis 53.88 9.94 262 319349 68035 46298416
Personality disorder 53.50 9.94 85 319526 3048 46363403
Diabetic retinopathy 53.15 9.94 72 319539 2230 46364221
Polydipsia 51.97 9.94 86 319525 3193 46363258
Arthritis 51.94 9.94 313 319298 77003 46289448
Drug resistance 51.89 9.94 27 319584 17341 46349110
Platelet count decreased 51.58 9.94 437 319174 99587 46266864
Therapeutic product effect incomplete 51.14 9.94 319 319292 77834 46288617
MELAS syndrome 50.98 9.94 22 319589 99 46366352
Multiple sclerosis relapse 50.96 9.94 135 319476 41990 46324461
Angina unstable 50.23 9.94 139 319472 7409 46359042
Loss of personal independence in daily activities 50.11 9.94 211 319400 56972 46309479
Peritonitis 49.95 9.94 41 319570 20673 46345778
Pneumocystis jirovecii pneumonia 49.72 9.94 21 319590 15227 46351224
Malignant neoplasm progression 48.97 9.94 253 319358 64673 46301778
Herpes zoster 48.68 9.94 269 319342 67603 46298848
Infective pulmonary exacerbation of cystic fibrosis 48.20 9.94 8 319603 10799 46355652
Coronary arterial stent insertion 48.16 9.94 77 319534 2776 46363675
Headache 47.98 9.94 2733 316878 475619 45890832
Transplant rejection 47.82 9.94 5 319606 9591 46356860
Pancreatitis chronic 46.96 9.94 60 319551 1753 46364698
Injection site erythema 46.55 9.94 308 319303 74119 46292332
Diabetic nephropathy 46.51 9.94 52 319559 1316 46365135
Anhidrosis 46.34 9.94 20 319591 90 46366361
Overdose 45.95 9.94 966 318645 101013 46265438
Atrioventricular block 45.89 9.94 126 319485 6685 46359766
Renal tubular necrosis 45.86 9.94 170 319441 10589 46355862
Hemiplegia 45.41 9.94 127 319484 6811 46359640
Product odour abnormal 45.33 9.94 47 319564 1089 46365362
Latent autoimmune diabetes in adults 45.11 9.94 13 319598 9 46366442
Acute coronary syndrome 44.98 9.94 163 319448 10041 46356410
Bladder cancer 44.82 9.94 77 319534 2949 46363502
Hypovolaemic shock 44.41 9.94 105 319506 5078 46361373
Bone erosion 44.39 9.94 6 319605 9437 46357014
Drug level above therapeutic 43.94 9.94 83 319528 3426 46363025
Adjustment disorder 43.87 9.94 51 319560 1348 46365103
Therapeutic response decreased 43.76 9.94 150 319461 42995 46323456
Hyperglycaemic hyperosmolar nonketotic syndrome 43.43 9.94 33 319578 498 46365953
Osteoporosis 43.38 9.94 138 319473 40470 46325981
Dialysis 43.25 9.94 160 319451 9956 46356495
Contusion 42.99 9.94 387 319224 87100 46279351
Cholelithiasis 42.82 9.94 429 319182 38252 46328199
Anaemia vitamin B12 deficiency 42.71 9.94 29 319582 363 46366088
C-reactive protein increased 42.68 9.94 231 319380 58359 46308092
Glomerular filtration rate decreased 41.93 9.94 175 319436 11519 46354932
Blood potassium increased 40.60 9.94 226 319385 16741 46349710
Mucosal inflammation 40.56 9.94 134 319477 38842 46327609
Hospitalisation 40.30 9.94 261 319350 63124 46303327
Haemophagocytic lymphohistiocytosis 39.94 9.94 5 319606 8337 46358114
Injection site reaction 39.83 9.94 180 319431 47669 46318782
Circulatory collapse 39.72 9.94 269 319342 21355 46345096
Duodenal ulcer perforation 38.58 9.94 6 319605 8496 46357955
Neurotoxicity 38.56 9.94 23 319588 13694 46352757
Immune-mediated myositis 38.55 9.94 39 319572 877 46365574
Cardiac arrest 38.38 9.94 849 318762 89550 46276901
Glycosylated haemoglobin abnormal 38.35 9.94 16 319595 65 46366386
Hepatic function abnormal 38.17 9.94 115 319496 34306 46332145
Blood triglycerides increased 38.16 9.94 171 319440 11612 46354839
Maternal exposure during pregnancy 38.11 9.94 484 319127 102065 46264386
Pain in jaw 37.85 9.94 135 319476 38237 46328214
Systemic infection 37.79 9.94 34 319577 657 46365794
Tenosynovitis 37.23 9.94 4 319607 7511 46358940
Peripheral swelling 37.05 9.94 812 318799 157259 46209192
Nasopharyngitis 36.99 9.94 788 318823 153210 46213241
Heart injury 36.92 9.94 44 319567 1195 46365256
Tubulointerstitial nephritis 36.74 9.94 199 319412 14589 46351862
Electrocardiogram T wave peaked 36.47 9.94 21 319590 192 46366259
Diabetic ketosis 36.46 9.94 20 319591 165 46366286
Exposure during pregnancy 36.24 9.94 984 318627 107228 46259223
Haematotoxicity 36.18 9.94 3 319608 6930 46359521
Device related infection 36.10 9.94 55 319556 20986 46345465
Urine albumin/creatinine ratio abnormal 35.92 9.94 9 319602 0 46366451
Colitis ulcerative 35.90 9.94 41 319570 17691 46348760
Product complaint 35.78 9.94 171 319440 11930 46354521
Rheumatoid nodule 35.42 9.94 9 319602 9011 46357440
Abdominal discomfort 35.29 9.94 777 318834 150388 46216063
Posterior reversible encephalopathy syndrome 35.24 9.94 31 319580 15110 46351341
Gastroenteritis 34.13 9.94 283 319328 23936 46342515
Persistent cloaca 33.83 9.94 20 319591 193 46366258
Kussmaul respiration 33.59 9.94 18 319593 141 46366310
Transient ischaemic attack 33.44 9.94 376 319235 34527 46331924
Febrile bone marrow aplasia 33.13 9.94 4 319607 6858 46359593
Diabetic ketoacidotic hyperglycaemic coma 32.97 9.94 14 319597 60 46366391
Multiple sclerosis 32.67 9.94 76 319535 24715 46341736
Toothache 32.65 9.94 210 319401 16382 46350069
Bradycardia 32.50 9.94 636 318975 65662 46300789
Oliguria 32.13 9.94 132 319479 8627 46357824
Therapy non-responder 31.80 9.94 159 319452 40993 46325458
Ischaemic cardiomyopathy 31.77 9.94 61 319550 2549 46363902
Erythema 31.67 9.94 740 318871 142080 46224371
Left ventricular hypertrophy 31.65 9.94 90 319521 4873 46361578
Osteonecrosis of jaw 31.35 9.94 125 319486 34277 46332174
Cerebral venous thrombosis 31.34 9.94 54 319557 2073 46364378
Confusional state 31.28 9.94 1366 318245 158526 46207925
Insulin C-peptide decreased 31.25 9.94 10 319601 14 46366437
Device dislocation 31.07 9.94 64 319547 21738 46344713
Stevens-Johnson syndrome 31.04 9.94 71 319540 23226 46343225
Diabetic ulcer 30.59 9.94 19 319592 202 46366249
Fluid overload 30.01 9.94 91 319520 27094 46339357
Oedematous pancreatitis 29.74 9.94 22 319589 318 46366133
High density lipoprotein decreased 29.71 9.94 48 319563 1746 46364705
Blood creatine phosphokinase increased 29.50 9.94 305 319306 27419 46339032
Haemofiltration 29.40 9.94 8 319603 3 46366448
Body mass index increased 29.35 9.94 36 319575 1008 46365443
Myocardial ischaemia 29.31 9.94 168 319443 12581 46353870
Intestinal malrotation 29.23 9.94 22 319589 327 46366124
Progressive multifocal leukoencephalopathy 29.21 9.94 21 319590 11325 46355126
Clostridium difficile infection 29.19 9.94 82 319529 25021 46341430
Immunodeficiency 29.12 9.94 28 319583 13078 46353373
Haemodynamic instability 28.80 9.94 117 319494 7608 46358843
Foreign body aspiration 28.67 9.94 17 319594 165 46366286
Status epilepticus 28.65 9.94 32 319579 13947 46352504
Constipation 28.58 9.94 941 318670 173156 46193295
Psoriasis 28.40 9.94 722 318889 77882 46288569
Pancreatic mass 28.40 9.94 32 319579 817 46365634
Musculoskeletal pain 28.33 9.94 325 319286 69803 46296648
Fungal infection 28.27 9.94 318 319293 29202 46337249
Mouth ulceration 28.09 9.94 92 319519 26740 46339711
Genital infection fungal 28.08 9.94 17 319594 172 46366279
Suicide attempt 28.01 9.94 531 319080 54505 46311946
Cholecystitis chronic 27.95 9.94 144 319467 10355 46356096
Myelosuppression 27.83 9.94 9 319602 7694 46358757
Bursitis 27.65 9.94 59 319552 19783 46346668
Anaemia macrocytic 27.51 9.94 58 319553 2595 46363856
Blood insulin decreased 27.49 9.94 8 319603 6 46366445
Bladder sphincter atony 27.36 9.94 16 319595 151 46366300
Prerenal failure 27.36 9.94 41 319570 1396 46365055
Anaemia megaloblastic 27.25 9.94 21 319590 324 46366127
Condition aggravated 27.09 9.94 1386 318225 243666 46122785
Inflammation 27.03 9.94 209 319402 48572 46317879
Vitamin B12 decreased 26.86 9.94 59 319552 2716 46363735
Aspergillus infection 26.82 9.94 7 319604 6883 46359568
Mobility decreased 26.81 9.94 275 319336 60319 46306132
Hypotension 26.55 9.94 1891 317720 230698 46135753
Osteonecrosis 26.45 9.94 89 319522 25655 46340796
Metabolic syndrome 26.42 9.94 38 319573 1246 46365205
Blood lactic acid 26.41 9.94 14 319597 107 46366344
Pulmonary arterial hypertension 26.39 9.94 90 319521 25838 46340613
Lymphopenia 26.22 9.94 40 319571 15253 46351198
Pharyngitis 26.15 9.94 208 319403 17375 46349076
Renal abscess 26.10 9.94 27 319584 624 46365827
IIIrd nerve paresis 26.08 9.94 13 319598 86 46366365
Immune reconstitution inflammatory syndrome 26.07 9.94 4 319607 5721 46360730
Hip arthroplasty 25.96 9.94 53 319558 18059 46348392
Lymphocyte count decreased 25.92 9.94 89 319522 25500 46340951
Angina pectoris 25.90 9.94 289 319322 26486 46339965
Albuminuria 25.64 9.94 17 319594 204 46366247
Blood pH decreased 25.59 9.94 56 319555 2571 46363880
Pleural effusion 25.35 9.94 407 319204 82545 46283906
Bone density decreased 25.17 9.94 18 319593 9734 46356717
Impaired healing 25.06 9.94 148 319463 36595 46329856
Product use in unapproved indication 24.97 9.94 451 319160 89822 46276629
Thrombotic microangiopathy 24.68 9.94 13 319598 8293 46358158
Osmolar gap 24.67 9.94 13 319598 98 46366353
Acute myeloid leukaemia 24.51 9.94 44 319567 15734 46350717
Diabetic foot 24.45 9.94 42 319569 1608 46364843
Discomfort 24.45 9.94 203 319408 46467 46319984
Generalised tonic-clonic seizure 24.43 9.94 99 319512 27023 46339428
Epstein-Barr virus infection 24.38 9.94 8 319603 6776 46359675
Diabetic hyperosmolar coma 24.33 9.94 22 319589 428 46366023
Allergic reaction to excipient 24.29 9.94 19 319592 300 46366151
Conjoined twins 24.17 9.94 18 319593 263 46366188
Creatinine renal clearance abnormal 24.06 9.94 16 319595 193 46366258
Complication associated with device 24.04 9.94 43 319568 15398 46351053
Shock hypoglycaemic 23.93 9.94 13 319598 105 46366346
Staphylococcal infection 23.91 9.94 145 319466 35626 46330825
Pathogen resistance 23.89 9.94 6 319605 6054 46360397
Cleft lip 23.52 9.94 13 319598 109 46366342
Chills 23.45 9.94 490 319121 95542 46270909
Bronchopulmonary aspergillosis 23.38 9.94 11 319600 7485 46358966
Macular oedema 22.95 9.94 71 319540 4030 46362421
Dry eye 22.94 9.94 118 319493 30204 46336247
Temperature perception test abnormal 22.93 9.94 8 319603 17 46366434
Oral herpes 22.80 9.94 63 319548 19327 46347124
Unevaluable event 22.79 9.94 204 319407 45971 46320480
Obesity 22.76 9.94 171 319440 14035 46352416
Abdominal pain 22.72 9.94 1849 317762 228182 46138269
Pruritus genital 22.70 9.94 25 319586 622 46365829
Pregnancy 22.63 9.94 102 319509 27035 46339416
Pyelonephritis acute 22.61 9.94 71 319540 4063 46362388
Thalamic infarction 22.56 9.94 23 319588 522 46365929
Cold sweat 22.45 9.94 140 319471 10805 46355646
Drug dependence 22.41 9.94 66 319545 19835 46346616
Gait inability 22.37 9.94 352 319259 34851 46331600
Basal cell carcinoma 22.32 9.94 69 319542 20418 46346033
Ischaemic stroke 22.29 9.94 193 319418 16529 46349922
Oxygen saturation decreased 22.27 9.94 336 319275 68828 46297623
Red blood cell sedimentation rate increased 22.26 9.94 81 319530 22808 46343643
Foot deformity 22.22 9.94 45 319566 15380 46351071
Blindness transient 22.10 9.94 61 319550 3246 46363205
Blood growth hormone increased 22.00 9.94 20 319591 392 46366059
Enthesopathy 22.00 9.94 3 319608 4687 46361764
Sopor 21.99 9.94 220 319391 19608 46346843
Glucose urine present 21.92 9.94 25 319586 647 46365804
Urine albumin/creatinine ratio increased 21.91 9.94 14 319597 157 46366294
Oropharyngeal pain 21.64 9.94 367 319244 73801 46292650
Stool analysis abnormal 21.57 9.94 10 319601 55 46366396
Glomerular filtration rate abnormal 21.56 9.94 22 319589 500 46365951
Product prescribing error 21.54 9.94 221 319390 19826 46346625
Anovulatory cycle 21.43 9.94 13 319598 132 46366319
Hypoglycaemic unconsciousness 21.42 9.94 26 319585 720 46365731
Injection site swelling 21.31 9.94 175 319436 40152 46326299
Pancreatic atrophy 21.28 9.94 12 319599 105 46366346
Clostridium difficile colitis 21.28 9.94 61 319550 18492 46347959
Exposure via ingestion 21.27 9.94 62 319549 3405 46363046
Unintentional medical device removal 21.15 9.94 3 319608 4550 46361901
Flushing 21.11 9.94 313 319298 64301 46302150
Intestinal perforation 20.99 9.94 26 319585 10825 46355626
Base excess negative 20.91 9.94 6 319605 4 46366447
Bronchostenosis 20.83 9.94 18 319593 329 46366122
Decreased appetite 20.76 9.94 1568 318043 192268 46174183
Dyslipidaemia 20.72 9.94 84 319527 5456 46360995
Body temperature decreased 20.70 9.94 160 319451 13249 46353202
Cytomegalovirus viraemia 20.69 9.94 3 319608 4475 46361976
Endometrial adenocarcinoma 20.60 9.94 32 319579 1125 46365326
Hyperinsulinaemic hypoglycaemia 20.43 9.94 9 319602 43 46366408
Overweight 20.39 9.94 57 319554 3056 46363395
Product substitution issue 20.31 9.94 174 319437 14857 46351594
Nephrogenic systemic fibrosis 20.27 9.94 4 319607 4768 46361683
Jaundice hepatocellular 20.09 9.94 8 319603 28 46366423
Mitochondrial enzyme deficiency 20.09 9.94 8 319603 28 46366423
Pneumothorax 19.97 9.94 44 319567 14585 46351866
Hepatosplenomegaly neonatal 19.96 9.94 5 319606 0 46366451
Multiple cardiac defects 19.96 9.94 5 319606 0 46366451
Mechanical ventilation complication 19.96 9.94 5 319606 0 46366451
Premature labour 19.91 9.94 29 319582 11270 46355181
Thirst 19.83 9.94 136 319475 10840 46355611
Peritonitis bacterial 19.80 9.94 18 319593 8635 46357816
Carcinoid tumour of the stomach 19.75 9.94 13 319598 154 46366297
CD30 expression 19.67 9.94 8 319603 30 46366421
Pancreaticoduodenectomy 19.67 9.94 8 319603 30 46366421
Disease recurrence 19.56 9.94 63 319548 18408 46348043
Apolipoprotein A-I decreased 19.47 9.94 8 319603 31 46366420
Oxygen saturation immeasurable 19.35 9.94 6 319605 7 46366444
Femur fracture 19.35 9.94 161 319450 36836 46329615
Dysentery 19.32 9.94 25 319586 740 46365711
Necrotising myositis 19.30 9.94 17 319594 319 46366132
Accidental overdose 19.14 9.94 216 319395 19850 46346601
Cough 19.08 9.94 1338 318273 228911 46137540
Accidental exposure to product 18.95 9.94 77 319534 21004 46345447
Hyperinsulinaemia 18.91 9.94 10 319601 76 46366375
Soft tissue disorder 18.89 9.94 3 319608 4183 46362268
Osmolar gap increased 18.88 9.94 7 319604 19 46366432
Suicidal ideation 18.81 9.94 272 319339 56110 46310341
Hyperhidrosis 18.80 9.94 769 318842 88539 46277912
Ascites 18.77 9.94 160 319451 36424 46330027
Nonalcoholic fatty liver disease 18.71 9.94 25 319586 764 46365687
Upper respiratory tract infection 18.70 9.94 314 319297 63242 46303209
Body temperature increased 18.67 9.94 97 319514 24764 46341687
Musculoskeletal disorder 18.66 9.94 50 319561 15495 46350956
Hepatic cirrhosis 18.64 9.94 177 319434 15555 46350896
Skin ulcer 18.48 9.94 138 319473 32320 46334131
Colitis 18.43 9.94 165 319446 37182 46329269
Neck pain 18.38 9.94 267 319344 55039 46311412
Intentional self-injury 18.31 9.94 94 319517 24072 46342379
Lymphadenopathy 18.30 9.94 144 319467 33344 46333107
Adrenal adenoma 18.27 9.94 26 319585 844 46365607
Congenital bladder anomaly 18.17 9.94 13 319598 178 46366273
Hypovolaemia 18.15 9.94 123 319488 9765 46356686
Cytokine release syndrome 18.11 9.94 10 319601 6213 46360238
Multiple organ dysfunction syndrome 18.10 9.94 473 319138 51237 46315214
Diffuse large B-cell lymphoma 18.08 9.94 9 319602 5929 46360522
Urachal abnormality 17.92 9.94 13 319598 182 46366269
Bone pain 17.90 9.94 220 319391 46670 46319781
Blood ketone body 17.87 9.94 8 319603 40 46366411
Blood phosphorus increased 17.86 9.94 51 319560 2768 46363683
Product blister packaging issue 17.75 9.94 13 319598 185 46366266
Congenital absence of bile ducts 17.71 9.94 8 319603 41 46366410
Hypertensive heart disease 17.68 9.94 48 319563 2530 46363921
Hyperphagia 17.67 9.94 36 319575 1572 46364879
Catheter site erythema 17.65 9.94 3 319608 3980 46362471
Insulin resistant diabetes 17.63 9.94 5 319606 3 46366448
Unresponsive to stimuli 17.61 9.94 314 319297 31860 46334591
Metastases to retroperitoneum 17.55 9.94 12 319599 152 46366299
Agranulocytosis 17.55 9.94 85 319526 22100 46344351
Pancreatic failure 17.54 9.94 21 319590 573 46365878
Hypoparathyroidism 17.53 9.94 22 319589 631 46365820
Non-alcoholic steatohepatitis 17.43 9.94 34 319577 1438 46365013
Medication error 17.39 9.94 303 319308 30608 46335843
Diabetic complication 17.37 9.94 27 319584 950 46365501
Serotonin syndrome 17.35 9.94 96 319515 24124 46342327
Optic neuritis 17.32 9.94 13 319598 6858 46359593
Congenital aortic valve stenosis 17.29 9.94 9 319602 66 46366385
Bundle branch block left 17.19 9.94 88 319523 6311 46360140
Pelvic fracture 17.19 9.94 33 319578 11506 46354945
Abdominal pain upper 17.19 9.94 1185 318426 144120 46222331
Autoimmune myositis 17.18 9.94 9 319602 67 46366384
Brain stem infarction 17.15 9.94 25 319586 830 46365621
Pulmonary fibrosis 17.07 9.94 75 319536 20017 46346434
Tinnitus 17.05 9.94 115 319496 27558 46338893
Creatinine renal clearance 17.04 9.94 5 319606 4 46366447
Glycosylated haemoglobin 17.04 9.94 5 319606 4 46366447
Dyskinesia 16.94 9.94 122 319489 28803 46337648
Eating disorder 16.93 9.94 164 319447 14490 46351961
Accidental underdose 16.88 9.94 21 319590 597 46365854
Knee arthroplasty 16.85 9.94 94 319517 23571 46342880
Cervix neoplasm 16.79 9.94 13 319598 202 46366249
Affect lability 16.71 9.94 103 319508 7917 46358534
Neuropathy, ataxia, retinitis pigmentosa syndrome 16.69 9.94 8 319603 48 46366403
Ankylosing spondylitis 16.66 9.94 13 319598 6724 46359727
Blood pressure inadequately controlled 16.64 9.94 67 319544 4339 46362112
Lung disorder 16.60 9.94 203 319408 43101 46323350
Basilar artery thrombosis 16.59 9.94 11 319600 132 46366319
Tuberculosis 16.51 9.94 28 319583 10237 46356214
Paraesthesia 16.47 9.94 647 318964 116790 46249661
Pancreatic enzymes increased 16.45 9.94 22 319589 673 46365778
Prothrombin consumption time prolonged 16.42 9.94 8 319603 50 46366401
Hunger 16.32 9.94 61 319550 3814 46362637
Vulvovaginal mycotic infection 16.30 9.94 66 319545 4285 46362166
Pulseless electrical activity 16.18 9.94 94 319517 7073 46359378
Prescription drug used without a prescription 16.13 9.94 32 319579 1370 46365081
Blood insulin increased 16.13 9.94 10 319601 106 46366345
Completed suicide 16.05 9.94 1183 318428 144737 46221714
Skinfold measurement 15.96 9.94 4 319607 0 46366451
Hyperfibrinogenaemia 15.96 9.94 4 319607 0 46366451
Ectopia cordis 15.96 9.94 4 319607 0 46366451
Pleural mesothelioma 15.96 9.94 4 319607 0 46366451
Blood lactate dehydrogenase increased 15.95 9.94 79 319532 20421 46346030
Incorrect route of product administration 15.91 9.94 58 319553 16325 46350126
Cystic fibrosis 15.86 9.94 3 319608 3685 46362766
Monoclonal B-cell lymphocytosis 15.80 9.94 7 319604 34 46366417
Differential white blood cell count abnormal 15.66 9.94 21 319590 644 46365807
Coronary artery occlusion 15.61 9.94 102 319509 8000 46358451
Therapeutic drug monitoring analysis not performed 15.60 9.94 18 319593 472 46365979
Joint stiffness 15.55 9.94 115 319496 26993 46339458
Transfusion 15.55 9.94 43 319568 13188 46353263
Congenital uterine anomaly 15.51 9.94 10 319601 114 46366337
Medullary thyroid cancer 15.51 9.94 10 319601 114 46366337
Pancreatectomy 15.51 9.94 6 319605 19 46366432
Flatulence 15.51 9.94 281 319330 28597 46337854
Bicuspid aortic valve 15.51 9.94 10 319601 114 46366337
Arteriosclerosis 15.51 9.94 117 319494 9616 46356835
Haemoglobin decreased 15.46 9.94 723 318888 128226 46238225
Dyspnoea 15.36 9.94 3207 316404 512341 45854110
Eyelid bleeding 15.32 9.94 7 319604 37 46366414
Injection site bruising 15.24 9.94 163 319448 35473 46330978
Macrosomia 15.22 9.94 8 319603 60 46366391
Disability 15.22 9.94 29 319582 10138 46356313
Pulmonary hypoplasia 15.21 9.94 14 319597 279 46366172
Bone disorder 15.13 9.94 78 319533 19955 46346496
Metastases to kidney 15.05 9.94 12 319599 195 46366256
Pancreatic carcinoma stage IV 15.03 9.94 7 319604 39 46366412
Anion gap abnormal 15.02 9.94 15 319596 332 46366119
Cutaneous T-cell dyscrasia 15 9.94 8 319603 62 46366389
Pneumonia aspiration 15.00 9.94 141 319470 31464 46334987
Device issue 14.98 9.94 78 319533 19902 46346549
Night sweats 14.98 9.94 117 319494 27133 46339318
Respiratory tract infection 14.97 9.94 132 319479 29840 46336611
Blood pressure systolic decreased 14.90 9.94 74 319537 5244 46361207
Large intestine perforation 14.84 9.94 18 319593 7562 46358889
Glucose tolerance impaired 14.82 9.94 69 319542 4762 46361689
Intestinal obstruction 14.78 9.94 111 319500 25964 46340487
Epileptic encephalopathy 14.76 9.94 13 319598 244 46366207
Ulcer 14.73 9.94 65 319546 17327 46349124
Resuscitation 14.67 9.94 27 319584 1092 46365359
Hyponatraemic encephalopathy 14.67 9.94 13 319598 246 46366205
Device difficult to use 14.64 9.94 20 319591 7984 46358467
Insulin-like growth factor increased 14.64 9.94 22 319589 751 46365700
Thyroglobulin increased 14.60 9.94 7 319604 42 46366409
Renal tubular acidosis 14.58 9.94 33 319578 1550 46364901
Liver disorder 14.50 9.94 174 319437 37072 46329379
Myxoedema coma 14.50 9.94 16 319595 399 46366052
Sleep disorder due to general medical condition, insomnia type 14.48 9.94 9 319602 5240 46361211
Persistent left superior vena cava 14.47 9.94 7 319604 43 46366408
Irritable bowel syndrome 14.43 9.94 61 319550 16454 46349997
Genital swelling 14.41 9.94 10 319601 130 46366321
Ill-defined disorder 14.36 9.94 116 319495 26711 46339740
Needle issue 14.35 9.94 78 319533 5726 46360725
Herpes simplex 14.30 9.94 17 319594 7206 46359245
Myopathy 14.29 9.94 107 319504 8774 46357677
Blood electrolytes abnormal 14.25 9.94 25 319586 974 46365477
Cardiotoxicity 14.21 9.94 15 319596 6707 46359744
Glycosuria 14.12 9.94 26 319585 1052 46365399
Scleroderma 14.12 9.94 7 319604 4622 46361829
Panniculitis 14.11 9.94 11 319600 5693 46360758
Drug withdrawal syndrome 13.94 9.94 120 319491 27264 46339187
Autoimmune nephritis 13.94 9.94 14 319597 312 46366139
Respiratory arrest 13.93 9.94 156 319455 33660 46332791
Malabsorption 13.87 9.94 57 319554 3726 46362725
Swollen tongue 13.84 9.94 279 319332 28953 46337498
Anxiety 13.84 9.94 1065 318546 180892 46185559
Diabetic foot infection 13.84 9.94 11 319600 178 46366273
Tooth disorder 13.79 9.94 98 319513 23205 46343246
Joint range of motion decreased 13.75 9.94 55 319556 15069 46351382
Reactive psychosis 13.75 9.94 4 319607 3 46366448
Cutaneous vasculitis 13.74 9.94 59 319552 3932 46362519
Blood pressure systolic increased 13.71 9.94 275 319336 28512 46337939
Spinal compression fracture 13.67 9.94 44 319567 12859 46353592
Malaise 13.65 9.94 2520 317091 328712 46037739
Hepatic enzyme increased 13.65 9.94 441 319170 81346 46285105
Back pain 13.62 9.94 1245 318366 208794 46157657
Wrong patient received product 13.61 9.94 34 319577 1703 46364748
Muscle necrosis 13.57 9.94 18 319593 546 46365905
Rash erythematous 13.55 9.94 160 319451 34190 46332261
Drug reaction with eosinophilia and systemic symptoms 13.52 9.94 133 319478 29415 46337036
PCO2 decreased 13.47 9.94 28 319583 1240 46365211
Pregnancy with contraceptive device 13.45 9.94 7 319604 4496 46361955
Blood growth hormone abnormal 13.40 9.94 6 319605 30 46366421
Glucose urine 13.38 9.94 5 319606 14 46366437
Hallucination 13.35 9.94 251 319360 49700 46316751
Depression 13.35 9.94 993 318618 169111 46197340
Asthma 13.35 9.94 502 319109 91040 46275411
Hyponatraemia 13.35 9.94 834 318777 100498 46265953
Postmenopausal haemorrhage 13.32 9.94 37 319574 1976 46364475
Tumour lysis syndrome 13.32 9.94 18 319593 7218 46359233
Increased appetite 13.30 9.94 102 319509 8425 46358026
Thyroid cancer recurrent 13.24 9.94 6 319605 31 46366420
Antipsychotic drug level increased 13.24 9.94 50 319561 3142 46363309
Metastases to bone 13.23 9.94 68 319543 17408 46349043
Venous aneurysm 13.22 9.94 4 319607 4 46366447
Diabetic cheiroarthropathy 13.22 9.94 4 319607 4 46366447
Injection site warmth 13.22 9.94 49 319562 13723 46352728
Helicobacter infection 13.16 9.94 39 319572 11697 46354754
Alkalosis hypochloraemic 13.16 9.94 10 319601 151 46366300
Hypereosinophilic syndrome 13.12 9.94 12 319599 237 46366214
Abnormal loss of weight 13.08 9.94 68 319543 4907 46361544
Central nervous system lesion 13.06 9.94 29 319582 9586 46356865
Early satiety 13.04 9.94 21 319590 762 46365689
Adrenal neoplasm 13.01 9.94 13 319598 288 46366163
Bladder neoplasm 12.99 9.94 17 319594 509 46365942
Pneumonitis 12.97 9.94 128 319483 28292 46338159
Rash maculo-papular 12.95 9.94 125 319486 27749 46338702
Cortisol increased 12.88 9.94 14 319597 343 46366108
Gallbladder oedema 12.87 9.94 11 319600 198 46366253
Vascular graft 12.86 9.94 21 319590 771 46365680
Inappropriate schedule of product administration 12.82 9.94 556 319055 64457 46301994
Hypogammaglobulinaemia 12.82 9.94 11 319600 5427 46361024
Hyporesponsive to stimuli 12.81 9.94 22 319589 842 46365609
Hypoglycaemia neonatal 12.77 9.94 23 319588 915 46365536
Hypophagia 12.67 9.94 276 319335 29030 46337421
Pollakiuria 12.66 9.94 235 319376 24026 46342425
Sinus arrest 12.65 9.94 33 319578 1698 46364753
Cardio-respiratory distress 12.59 9.94 9 319602 123 46366328
Hypertensive angiopathy 12.58 9.94 8 319603 89 46366362
Tumour compression 12.52 9.94 6 319605 36 46366415
Drug eruption 12.47 9.94 90 319521 21239 46345212
Suspected suicide 12.45 9.94 64 319547 4597 46361854
Pancreatic injury 12.45 9.94 5 319606 18 46366433
Insulin-requiring type 2 diabetes mellitus 12.44 9.94 7 319604 61 46366390
Enterochromaffin cell hyperplasia 12.44 9.94 7 319604 61 46366390
Deformity 12.42 9.94 19 319592 7238 46359213
Neoplasm malignant 12.40 9.94 102 319509 23397 46343054
Interstitial lung disease 12.37 9.94 278 319333 53671 46312780
Device use error 12.32 9.94 10 319601 5071 46361380
Abortion induced 12.31 9.94 33 319578 10227 46356224
Neuropathy peripheral 12.26 9.94 503 319108 90390 46276061
Pancreatic neoplasm 12.25 9.94 20 319591 734 46365717
Decreased bronchial secretion 12.25 9.94 7 319604 63 46366388
Brain oedema 12.24 9.94 44 319567 12434 46354017
Treatment noncompliance 12.22 9.94 278 319333 29453 46336998
Incorrect dose administered 12.20 9.94 403 319208 45147 46321304
Binge eating 12.16 9.94 14 319597 366 46366085
Fibromyalgia 12.13 9.94 176 319435 36287 46330164
Diet failure 12.12 9.94 6 319605 39 46366412
Lupus-like syndrome 12.07 9.94 22 319589 7822 46358629
Cholangiectasis acquired 12.04 9.94 5 319606 20 46366431
Sprue-like enteropathy 12.01 9.94 15 319596 428 46366023
Central obesity 12.01 9.94 21 319590 816 46365635
Fluid retention 12.00 9.94 262 319349 50784 46315667
Retinal artery thrombosis 12.00 9.94 8 319603 97 46366354
Base excess decreased 11.98 9.94 7 319604 66 46366385
Diffuse idiopathic skeletal hyperostosis 11.97 9.94 3 319608 0 46366451
Nipple swelling 11.97 9.94 3 319608 0 46366451
Blood corticotrophin abnormal 11.97 9.94 3 319608 0 46366451
Blood osmolarity abnormal 11.97 9.94 4 319607 7 46366444
Urosepsis 11.93 9.94 159 319452 15194 46351257
Bronchiectasis 11.92 9.94 29 319582 9287 46357164
Motor dysfunction 11.86 9.94 88 319523 7194 46359257
Polycystic ovaries 11.82 9.94 28 319583 1356 46365095
Anaphylactic reaction 11.81 9.94 275 319336 52837 46313614
Eructation 11.80 9.94 88 319523 7207 46359244
Diabetic coma 11.79 9.94 20 319591 758 46365693
Urine ketone body 11.78 9.94 9 319602 137 46366314
Fluid intake reduced 11.78 9.94 50 319561 3316 46363135
Atrioventricular block complete 11.77 9.94 91 319520 7536 46358915
Device breakage 11.76 9.94 31 319580 9661 46356790
Transcription medication error 11.70 9.94 10 319601 180 46366271
Conjunctivitis 11.68 9.94 60 319551 15364 46351087
Genital erythema 11.67 9.94 5 319606 22 46366429
Pneumonia viral 11.67 9.94 17 319594 6607 46359844
Aplasia pure red cell 11.64 9.94 8 319603 4417 46362034
Cervical dysplasia 11.59 9.94 3 319608 2966 46363485
Distributive shock 11.58 9.94 16 319595 505 46365946
Akathisia 11.55 9.94 22 319589 7692 46358759
Uterine perforation 11.53 9.94 20 319591 7247 46359204
Urine output increased 11.52 9.94 26 319585 1219 46365232
Gallbladder disorder 11.51 9.94 176 319435 17322 46349129
Dystonia 11.51 9.94 39 319572 11218 46355233
Psychogenic tremor 11.50 9.94 5 319606 23 46366428
Hypergastrinaemia 11.46 9.94 8 319603 105 46366346
Neurofibrosarcoma 11.46 9.94 9 319602 143 46366308
Left atrial dilatation 11.46 9.94 33 319578 1800 46364651
Abortion spontaneous 11.46 9.94 220 319391 43426 46323025
Hyperventilation 11.44 9.94 72 319539 5575 46360876
Neuroendocrine tumour 11.36 9.94 17 319594 578 46365873
Encephalitis 11.36 9.94 21 319590 7427 46359024
Cell death 11.34 9.94 38 319573 2250 46364201
Base excess 11.33 9.94 5 319606 24 46366427
Nodular rash 11.30 9.94 10 319601 189 46366262
Urine output decreased 11.29 9.94 121 319490 10976 46355475
Enterococcal infection 11.29 9.94 19 319592 6968 46359483
Muscle injury 11.28 9.94 10 319601 4856 46361595
Mental disability 11.27 9.94 8 319603 108 46366343
Visceral congestion 11.27 9.94 12 319599 287 46366164
Infusion site erythema 11.26 9.94 22 319589 7620 46358831
Low density lipoprotein increased 11.23 9.94 75 319536 5925 46360526
Cardiac disorder 11.23 9.94 386 319225 43472 46322979
Food craving 11.22 9.94 25 319586 1162 46365289
Pulmonary haemorrhage 11.16 9.94 17 319594 6488 46359963
Device deployment issue 11.14 9.94 5 319606 3498 46362953
Haemorrhage 11.14 9.94 288 319323 54581 46311870
Metastases to fallopian tube 11.09 9.94 6 319605 48 46366403
Coronary angioplasty 11.09 9.94 8 319603 111 46366340
Duodenal ulcer haemorrhage 11.07 9.94 39 319572 2369 46364082
Vulvovaginitis 11.04 9.94 12 319599 294 46366157
Renal cancer 11.04 9.94 47 319564 3121 46363330
Sensory loss 11.01 9.94 83 319528 6819 46359632
Metabolic encephalopathy 11.01 9.94 69 319542 5334 46361117
Empty sella syndrome 11.01 9.94 5 319606 26 46366425
Increased tendency to bruise 10.98 9.94 31 319580 9443 46357008
Genital rash 10.97 9.94 15 319596 469 46365982
Serum ferritin increased 10.93 9.94 12 319599 5271 46361180
Red cell distribution width abnormal 10.90 9.94 9 319602 154 46366297
Right ventricular failure 10.88 9.94 65 319546 16028 46350423
Throat irritation 10.88 9.94 136 319475 28765 46337686
Grip strength decreased 10.85 9.94 27 319584 8579 46357872
Bacteraemia 10.83 9.94 55 319556 14124 46352327
Spinal fracture 10.78 9.94 61 319550 15244 46351207
Endometrial cancer stage II 10.75 9.94 4 319607 11 46366440
IIIrd nerve paralysis 10.75 9.94 18 319593 675 46365776
Leiomyoma 10.74 9.94 13 319598 359 46366092
Metastases to central nervous system 10.72 9.94 40 319571 11181 46355270
Vulvovaginal pruritus 10.71 9.94 39 319572 2408 46364043
Enterocolitis 10.70 9.94 16 319595 6152 46360299
Ovarian adenoma 10.67 9.94 11 319600 253 46366198
Epistaxis 10.67 9.94 347 319264 63958 46302493
Joint effusion 10.67 9.94 44 319567 11951 46354500
Respiratory depression 10.66 9.94 42 319569 11558 46354893
Gastrointestinal carcinoma 10.65 9.94 25 319586 1203 46365248
Pulmonary tuberculosis 10.64 9.94 10 319601 4721 46361730
Cholestatic liver injury 10.62 9.94 35 319576 2055 46364396
Demyelination 10.58 9.94 14 319597 5666 46360785
Hypertensive crisis 10.58 9.94 141 319470 13474 46352977
Helicobacter gastritis 10.57 9.94 28 319583 1454 46364997
Bradyarrhythmia 10.56 9.94 34 319577 1972 46364479
Rhinorrhoea 10.54 9.94 247 319364 47418 46319033
Sedation 10.53 9.94 103 319508 22807 46343644
Inappropriate antidiuretic hormone secretion 10.53 9.94 145 319466 13957 46352494
Lichen planus 10.51 9.94 32 319579 1801 46364650
Sudden cardiac death 10.48 9.94 36 319575 2159 46364292
Neutropenic sepsis 10.47 9.94 46 319565 12278 46354173
Acid base balance abnormal 10.47 9.94 11 319600 259 46366192
Incision site swelling 10.43 9.94 5 319606 30 46366421
Blood urea increased 10.40 9.94 237 319374 25115 46341336
Endometrial hyperplasia 10.39 9.94 19 319592 765 46365686
Sepsis 10.35 9.94 796 318815 135218 46231233
Skin lesion 10.32 9.94 125 319486 26588 46339863
Genital infection 10.32 9.94 6 319605 56 46366395
Malnutrition 10.31 9.94 55 319556 13948 46352503
Blood bicarbonate abnormal 10.30 9.94 5 319606 31 46366420
Pancreatic pseudocyst 10.29 9.94 16 319595 563 46365888
Mood swings 10.28 9.94 67 319544 16185 46350266
Benign pancreatic neoplasm 10.27 9.94 4 319607 13 46366438
Influenza like illness 10.19 9.94 308 319303 57262 46309189
Alanine aminotransferase increased 10.19 9.94 498 319113 87953 46278498
Skin turgor decreased 10.18 9.94 15 319596 503 46365948
Hypoglycaemic seizure 10.18 9.94 15 319596 503 46365948
Renal injury 10.16 9.94 105 319506 9436 46357015
Emphysematous pyelonephritis 10.09 9.94 9 319602 172 46366279
Foetal hypokinesia 10.08 9.94 14 319597 444 46366007
Skin necrosis 10.08 9.94 28 319583 8576 46357875
Drug half-life increased 10.04 9.94 4 319607 14 46366437
Retinal vascular disorder 10.00 9.94 9 319602 174 46366277
Hypertensive emergency 9.99 9.94 29 319582 1589 46364862
Miosis 9.95 9.94 19 319592 6638 46359813

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 8786.04 11.09 4738 275873 26475 29645392
Hypoglycaemia 1846.37 11.09 2330 278281 48651 29623216
Diabetic ketoacidosis 1698.41 11.09 1317 279294 14669 29657198
Acute kidney injury 1605.85 11.09 5908 274703 267934 29403933
Blood glucose increased 1241.23 11.09 2135 278476 59395 29612472
Metabolic acidosis 1225.49 11.09 1629 278982 35832 29636035
Glycosylated haemoglobin increased 774.66 11.09 671 279940 8820 29663047
Diabetes mellitus inadequate control 740.11 11.09 746 279865 12016 29659851
Euglycaemic diabetic ketoacidosis 618.43 11.09 317 280294 1554 29670313
Myocardial infarction 613.65 11.09 2565 278046 123060 29548807
Hyperkalaemia 571.94 11.09 1632 278979 64378 29607489
Ketoacidosis 529.76 11.09 367 280244 3379 29668488
Pancreatitis 514.43 11.09 1088 279523 35402 29636465
Hyperglycaemia 461.23 11.09 1019 279592 34181 29637686
Coronary artery disease 443.05 11.09 1242 279369 48470 29623397
Pancreatitis acute 353.80 11.09 759 279852 24936 29646931
Drug abuse 320.95 11.09 185 280426 81887 29589980
Death 317.41 11.09 2006 278605 355277 29316590
Pemphigoid 299.15 11.09 361 280250 7167 29664700
Hyperlactacidaemia 281.57 11.09 217 280394 2389 29669478
Cardiac failure congestive 264.32 11.09 1519 279092 82888 29588979
Febrile neutropenia 252.73 11.09 380 280231 106313 29565554
Pancreatic carcinoma 250.09 11.09 337 280274 7500 29664367
Pyrexia 248.16 11.09 1679 278932 292810 29379057
Off label use 240.71 11.09 1362 279249 247928 29423939
Neutropenia 226.34 11.09 547 280064 127993 29543874
Diabetic metabolic decompensation 224.21 11.09 146 280465 1200 29670667
Hypoglycaemic coma 221.56 11.09 180 280431 2151 29669716
Pneumonia 208.88 11.09 2065 278546 332241 29339626
Blood glucose abnormal 208.64 11.09 252 280359 5007 29666860
Blood lactic acid increased 203.50 11.09 262 280349 5568 29666299
Shock 203.36 11.09 571 280040 22288 29649579
Bladder cancer 196.56 11.09 326 280285 8776 29663091
Blood glucose decreased 194.09 11.09 398 280213 12655 29659212
Blood glucose fluctuation 194.09 11.09 204 280407 3457 29668410
Diabetes mellitus 192.31 11.09 840 279771 41025 29630842
Type 2 diabetes mellitus 163.45 11.09 381 280230 13241 29658626
Platelet count decreased 162.29 11.09 484 280127 105645 29566222
Drug ineffective 159.36 11.09 2240 278371 338147 29333720
Product use in unapproved indication 147.41 11.09 292 280319 73401 29598466
Cerebrovascular accident 146.78 11.09 1307 279304 82170 29589697
Cytomegalovirus infection 146.74 11.09 23 280588 23651 29648216
Thrombocytopenia 141.72 11.09 731 279880 136313 29535554
Pancytopenia 137.99 11.09 377 280234 84675 29587192
Ketonuria 137.58 11.09 80 280531 524 29671343
Intentional overdose 135.94 11.09 756 279855 40725 29631142
Diabetic neuropathy 133.63 11.09 175 280436 3784 29668083
Weight decreased 128.42 11.09 2056 278555 148865 29523002
White blood cell count decreased 123.90 11.09 389 280222 83558 29588309
Vitamin B12 deficiency 123.78 11.09 137 280474 2468 29669399
Anuria 123.18 11.09 288 280323 10028 29661839
Coronary artery bypass 122.51 11.09 193 280418 4969 29666898
Leukopenia 115.35 11.09 219 280392 55940 29615927
Seizure 114.17 11.09 504 280107 97971 29573896
Pancreatic carcinoma metastatic 110.32 11.09 144 280467 3103 29668764
Rheumatoid arthritis 109.26 11.09 135 280476 41062 29630805
Bone marrow failure 106.90 11.09 74 280537 29711 29642156
Plasma cell myeloma 105.89 11.09 213 280398 53249 29618618
Lipase increased 104.45 11.09 243 280368 8433 29663434
Toe amputation 103.29 11.09 116 280495 2125 29669742
Drug resistance 101.68 11.09 31 280580 20102 29651765
Myocardial ischaemia 101.52 11.09 375 280236 16942 29654925
Acidosis 101.27 11.09 267 280344 10034 29661833
Acute myocardial infarction 100.89 11.09 844 279767 52095 29619772
Product residue present 97.65 11.09 123 280488 2555 29669312
Treatment failure 96.93 11.09 109 280502 34570 29637297
Neutrophil count decreased 96.77 11.09 155 280456 42299 29629568
Disease progression 96.73 11.09 402 280209 79472 29592395
Completed suicide 95.95 11.09 1385 279226 98107 29573760
Anion gap increased 95.10 11.09 97 280514 1584 29670283
Renal failure 92.28 11.09 1709 278902 127257 29544610
Infusion related reaction 87.01 11.09 154 280457 40410 29631457
Continuous haemodiafiltration 84.12 11.09 75 280536 1026 29670841
Vomiting 82.60 11.09 2667 277944 217151 29454716
Heart injury 80.06 11.09 83 280528 1383 29670484
Injection site nodule 78.64 11.09 82 280529 1376 29670491
Pneumocystis jirovecii pneumonia 78.47 11.09 31 280580 17089 29654778
Graft versus host disease 78.43 11.09 4 280607 10146 29661721
Polyuria 77.63 11.09 195 280416 7111 29664756
Urine ketone body present 77.41 11.09 68 280543 911 29670956
Malignant neoplasm progression 75.51 11.09 384 280227 71903 29599964
Adenocarcinoma pancreas 75.22 11.09 78 280533 1300 29670567
Ketosis 75.16 11.09 46 280565 335 29671532
Drug dependence 73.67 11.09 55 280556 21240 29650627
Toxic epidermal necrolysis 73.60 11.09 38 280573 17902 29653965
Hepatic function abnormal 73.29 11.09 179 280432 41766 29630101
Immune-mediated myositis 72.43 11.09 74 280537 1211 29670656
Coronary arterial stent insertion 72.17 11.09 136 280475 4058 29667809
Pancreatitis chronic 71.60 11.09 86 280525 1698 29670169
Diabetic retinopathy 71.29 11.09 85 280526 1665 29670202
Infective pulmonary exacerbation of cystic fibrosis 67.46 11.09 3 280608 8569 29663298
Alanine aminotransferase increased 67.02 11.09 414 280197 73862 29598005
Stomatitis 65.99 11.09 158 280453 37121 29634746
Haemodialysis 65.08 11.09 240 280371 10833 29661034
Bronchopulmonary aspergillosis 63.71 11.09 18 280593 12266 29659601
Aspartate aminotransferase increased 63.38 11.09 342 280269 63080 29608787
Diarrhoea 61.35 11.09 3766 276845 330337 29341530
Angina unstable 61.12 11.09 253 280358 12057 29659810
Diabetic foot infection 61.08 11.09 52 280559 666 29671201
Aspergillus infection 60.91 11.09 11 280600 10203 29661664
Hypomagnesaemia 60.81 11.09 312 280299 16286 29655581
Balanoposthitis 60.71 11.09 62 280549 1014 29670853
MELAS syndrome 60.13 11.09 19 280592 13 29671854
Peritonitis 59.93 11.09 67 280544 21308 29650559
Acetonaemia 59.28 11.09 25 280586 70 29671797
Transplant rejection 59.24 11.09 8 280603 9198 29662669
Rash 58.02 11.09 1362 279249 190527 29481340
Blood lactic acid 57.92 11.09 39 280572 341 29671526
Posterior reversible encephalopathy syndrome 57.39 11.09 7 280604 8700 29663167
Acute coronary syndrome 56.05 11.09 264 280347 13309 29658558
Infection 55.48 11.09 466 280145 77608 29594259
Sepsis 54.90 11.09 1003 279608 145392 29526475
Peritonitis bacterial 54.84 11.09 19 280592 11359 29660508
Condition aggravated 54.74 11.09 935 279676 136931 29534936
Ischaemic cardiomyopathy 54.71 11.09 156 280455 6141 29665726
Neuropathy peripheral 54.06 11.09 412 280199 70063 29601804
Pancreatic neoplasm 53.64 11.09 55 280556 904 29670963
Septic shock 53.57 11.09 362 280249 63245 29608622
Drug intolerance 53.53 11.09 230 280381 45061 29626806
Hallucination 53.29 11.09 257 280354 48802 29623065
Intentional product use issue 52.91 11.09 170 280441 36270 29635597
Kidney transplant rejection 52.14 11.09 5 280606 7504 29664363
Microalbuminuria 52.13 11.09 45 280566 588 29671279
Immune reconstitution inflammatory syndrome 51.75 11.09 11 280600 9090 29662777
Suicide attempt 50.90 11.09 547 280064 36150 29635717
Drug level increased 50.75 11.09 320 280291 18034 29653833
Blood pH decreased 50.62 11.09 83 280528 2212 29669655
Hospitalisation 50.60 11.09 228 280383 44091 29627776
Aggression 50.30 11.09 177 280434 36730 29635137
Pathogen resistance 50.27 11.09 9 280602 8401 29663466
Diabetic nephropathy 50.17 11.09 74 280537 1795 29670072
Haemoglobin decreased 49.53 11.09 761 279850 113337 29558530
Disseminated intravascular coagulation 49.53 11.09 82 280529 22089 29649778
Hypoxia 49.51 11.09 255 280356 47599 29624268
Interstitial lung disease 49.50 11.09 345 280266 59852 29612015
Latent autoimmune diabetes in adults 49.23 11.09 18 280593 29 29671838
Cardiovascular disorder 48.16 11.09 217 280394 10735 29661132
Dehydration 48.13 11.09 1506 279105 122033 29549834
Genital infection fungal 47.94 11.09 27 280584 165 29671702
Hypothermia 47.01 11.09 196 280415 9371 29662496
Mucosal inflammation 46.59 11.09 139 280472 30355 29641512
Glomerular filtration rate decreased 46.19 11.09 220 280391 11142 29660725
Obesity 44.99 11.09 179 280432 8376 29663491
Foetal exposure during pregnancy 44.95 11.09 185 280426 36686 29635181
Lymphocyte count decreased 44.91 11.09 68 280543 18987 29652880
Blood ketone body increased 44.51 11.09 33 280578 341 29671526
Urine albumin/creatinine ratio abnormal 44.16 11.09 12 280599 0 29671867
Product odour abnormal 44.12 11.09 40 280571 560 29671307
Anxiety 44.07 11.09 585 280026 89286 29582581
Osteonecrosis 43.69 11.09 52 280559 16083 29655784
Drug reaction with eosinophilia and systemic symptoms 43.42 11.09 130 280481 28358 29643509
Haemophagocytic lymphohistiocytosis 42.82 11.09 19 280592 9772 29662095
Clostridium difficile infection 42.59 11.09 51 280560 15732 29656135
Cytokine release syndrome 42.32 11.09 20 280591 9913 29661954
Urine ketone body 41.25 11.09 17 280594 44 29671823
Deep vein thrombosis 41.24 11.09 365 280246 60136 29611731
Glycosylated haemoglobin decreased 40.99 11.09 31 280580 331 29671536
Pseudomonas infection 40.40 11.09 24 280587 10458 29661409
Angina pectoris 40.01 11.09 438 280173 29080 29642787
Hepatic steatosis 39.71 11.09 256 280355 14537 29657330
Cardiogenic shock 39.42 11.09 282 280329 16579 29655288
Cytomegalovirus viraemia 39.29 11.09 4 280607 5725 29666142
Polydipsia 38.98 11.09 97 280514 3516 29668351
Suspected suicide 38.56 11.09 89 280522 3072 29668795
Insomnia 38.32 11.09 629 279982 92707 29579160
Synovitis 38.27 11.09 22 280589 9761 29662106
Anaemia 37.96 11.09 1578 279033 206414 29465453
Arteriosclerosis 37.18 11.09 200 280411 10633 29661234
Progressive multifocal leukoencephalopathy 37.11 11.09 19 280592 8994 29662873
Exposure via ingestion 36.92 11.09 78 280533 2533 29669334
Osmolar gap increased 36.80 11.09 10 280601 0 29671867
Joint swelling 36.68 11.09 273 280338 46673 29625194
Epstein-Barr virus infection 36.34 11.09 9 280602 6697 29665170
Obstructive pancreatitis 36.22 11.09 30 280581 369 29671498
Starvation ketoacidosis 35.95 11.09 12 280599 12 29671855
Tongue oedema 35.83 11.09 80 280531 2700 29669167
Therapy non-responder 35.77 11.09 148 280463 29305 29642562
Glycosylated haemoglobin abnormal 35.63 11.09 18 280593 85 29671782
Arthralgia 35.57 11.09 984 279627 134807 29537060
Musculoskeletal stiffness 35.55 11.09 194 280417 35687 29636180
Chills 35.41 11.09 471 280140 71867 29600000
Diabetic foot 35.38 11.09 79 280532 2666 29669201
Osteonecrosis of jaw 35.30 11.09 76 280535 18542 29653325
Therapeutic product effect decreased 34.75 11.09 147 280464 28929 29642938
Drug hypersensitivity 34.69 11.09 443 280168 68076 29603791
Blood bicarbonate decreased 34.31 11.09 72 280539 2327 29669540
Osmolar gap 34.13 11.09 13 280598 25 29671842
Neurotoxicity 34.10 11.09 44 280567 13138 29658729
Myelosuppression 33.98 11.09 13 280598 7309 29664558
Stevens-Johnson syndrome 33.84 11.09 71 280540 17485 29654382
Vitamin B12 decreased 33.53 11.09 45 280566 997 29670870
Exposure during pregnancy 33.23 11.09 23 280588 9238 29662629
Respiratory arrest 33.10 11.09 151 280460 29107 29642760
Overdose 32.51 11.09 1027 279584 83310 29588557
Glycosuria 32.48 11.09 50 280561 1261 29670606
Diabetic ketoacidotic hyperglycaemic coma 32.31 11.09 20 280591 149 29671718
Thirst 32.31 11.09 140 280471 6809 29665058
Pancreatic neuroendocrine tumour 32.30 11.09 23 280588 222 29671645
Pancreaticoduodenectomy 32.20 11.09 15 280596 57 29671810
Pollakiuria 31.89 11.09 269 280342 16637 29655230
Pulmonary haemorrhage 31.54 11.09 25 280586 9367 29662500
Naevus flammeus 31.42 11.09 19 280592 135 29671732
Abdominal pain 31.41 11.09 1563 279048 134091 29537776
Glucose urine present 31.28 11.09 41 280570 887 29670980
Epilepsy 30.76 11.09 92 280519 20077 29651790
Neoplasm progression 30.63 11.09 78 280533 17945 29653922
Nephrogenic systemic fibrosis 30.11 11.09 3 280608 4368 29667499
Pneumothorax 29.96 11.09 67 280544 16126 29655741
Bladder transitional cell carcinoma 29.85 11.09 69 280542 2384 29669483
Coma 29.54 11.09 538 280073 39911 29631956
Myelodysplastic syndrome 29.11 11.09 85 280526 18693 29653174
Anion gap 29.03 11.09 33 280578 613 29671254
Dystonia 28.93 11.09 29 280582 9698 29662169
Haemodynamic instability 28.89 11.09 150 280461 7865 29664002
Sinusitis 28.45 11.09 189 280422 33156 29638711
C-reactive protein increased 28.43 11.09 265 280346 43208 29628659
Haemoptysis 28.12 11.09 173 280438 30905 29640962
Cholelithiasis 27.81 11.09 301 280310 19924 29651943
Depression 27.79 11.09 640 279971 89797 29582070
Hypoalbuminaemia 27.70 11.09 38 280573 11054 29660813
Colitis 27.66 11.09 172 280439 30648 29641219
Bile duct stent insertion 27.54 11.09 15 280596 85 29671782
Staphylococcal infection 27.48 11.09 168 280443 30056 29641811
Pain 27.34 11.09 1330 279281 171311 29500556
Distributive shock 27.34 11.09 32 280579 614 29671253
Substance abuse 27.30 11.09 16 280595 7024 29664843
Antipsychotic drug level decreased 27.19 11.09 37 280574 831 29671036
Urine output increased 27.13 11.09 41 280570 1017 29670850
Headache 27.04 11.09 1414 279197 180892 29490975
Haematotoxicity 26.94 11.09 12 280599 6158 29665709
Drug interaction 26.82 11.09 2194 278417 197374 29474493
Haemorrhage 26.76 11.09 289 280322 45790 29626077
Therapeutic response decreased 26.75 11.09 127 280484 24222 29647645
Diabetic ketosis 26.72 11.09 12 280599 41 29671826
Herpes zoster 26.41 11.09 168 280443 29775 29642092
Diabetic eye disease 26.31 11.09 13 280598 58 29671809
Pneumonia aspiration 26.14 11.09 227 280384 37553 29634314
Acute myeloid leukaemia 26.13 11.09 84 280527 17922 29653945
Delirium 26 11.09 249 280362 40382 29631485
Macular oedema 25.93 11.09 70 280541 2668 29669199
Suicidal ideation 25.88 11.09 215 280396 35899 29635968
C-reactive protein abnormal 25.84 11.09 10 280601 5583 29666284
Alveolar capillary dysplasia 25.76 11.09 7 280604 0 29671867
Migraine 25.72 11.09 51 280560 12823 29659044
Unevaluable event 25.71 11.09 183 280428 31602 29640265
Diabetic macroangiopathy 25.60 11.09 8 280603 5 29671862
Intestinal obstruction 25.60 11.09 93 280518 19119 29652748
Psychotic disorder 25.57 11.09 109 280502 21406 29650461
Blood triglycerides increased 25.37 11.09 221 280390 13796 29658071
Blood ketone body 25.31 11.09 13 280598 64 29671803
Toxicity to various agents 25.12 11.09 1956 278655 175227 29496640
Enterococcal infection 25.06 11.09 24 280587 8200 29663667
Arteriosclerosis coronary artery 25.02 11.09 185 280426 10991 29660876
Product use issue 24.99 11.09 293 280318 45723 29626144
Pancreatic pseudocyst 24.88 11.09 34 280577 767 29671100
Drug withdrawal syndrome 24.39 11.09 99 280512 19710 29652157
Basilar artery thrombosis 24.31 11.09 15 280596 111 29671756
Balanitis candida 24.20 11.09 15 280596 112 29671755
Vitreous haemorrhage 24.20 11.09 58 280553 2052 29669815
Immunosuppressant drug level increased 24.18 11.09 7 280604 4695 29667172
Restlessness 24.17 11.09 119 280492 22480 29649387
Respiratory failure 24.15 11.09 738 279873 99904 29571963
Epistaxis 24.12 11.09 350 280261 52631 29619236
Thrombotic microangiopathy 24.12 11.09 27 280584 8583 29663284
Blood lactate dehydrogenase increased 24.10 11.09 105 280506 20496 29651371
Blood bilirubin increased 24.09 11.09 223 280388 36413 29635454
5-hydroxyindolacetic acid in urine increased 23.81 11.09 18 280593 192 29671675
Actinic elastosis 23.78 11.09 11 280600 41 29671826
Intestinal perforation 23.55 11.09 27 280584 8492 29663375
Blood mercury abnormal 23.55 11.09 17 280594 168 29671699
Anaemia vitamin B12 deficiency 23.45 11.09 21 280590 289 29671578
Premature baby 23.44 11.09 79 280532 16612 29655255
Acquired phimosis 23.38 11.09 12 280599 59 29671808
Renal tubular necrosis 23.35 11.09 232 280379 15019 29656848
Nasopharyngitis 23.35 11.09 399 280212 58450 29613417
Osteoporosis 23.29 11.09 40 280571 10623 29661244
Hyperoxaluria 22.96 11.09 15 280596 124 29671743
Essential hypertension 22.95 11.09 63 280548 2425 29669442
Neuropathic arthropathy 22.68 11.09 16 280595 152 29671715
Phimosis 22.56 11.09 29 280582 615 29671252
Productive cough 22.53 11.09 176 280435 29777 29642090
Cornea verticillata 22.52 11.09 10 280601 33 29671834
Tumour lysis syndrome 22.49 11.09 55 280556 12830 29659037
Transient ischaemic attack 22.36 11.09 346 280265 24854 29647013
Lymphopenia 22.34 11.09 57 280554 13106 29658761
Ileus 22.27 11.09 73 280538 15482 29656385
Device related infection 22.25 11.09 83 280528 16932 29654935
Pancreatitis necrotising 22.22 11.09 61 280550 2348 29669519
Cardiomyopathy 22.06 11.09 228 280383 14915 29656952
Pancreatic carcinoma stage III 22.03 11.09 7 280604 5 29671862
Hypoglycaemic encephalopathy 22.02 11.09 18 280593 217 29671650
Abnormal behaviour 21.97 11.09 145 280466 25478 29646389
Drug level above therapeutic 21.93 11.09 69 280542 2870 29668997
Pneumonia bacterial 21.73 11.09 34 280577 9369 29662498
Food aversion 21.66 11.09 20 280591 287 29671580
Serotonin syndrome 21.66 11.09 90 280521 17801 29654066
Cytomegalovirus test positive 21.57 11.09 4 280607 3641 29668226
Low density lipoprotein abnormal 21.48 11.09 19 280592 257 29671610
Therapeutic product effect incomplete 21.37 11.09 208 280403 33626 29638241
Tremor 21.31 11.09 540 280071 74823 29597044
Burkholderia pseudomallei infection 21.27 11.09 10 280601 39 29671828
Albumin urine present 21.15 11.09 22 280589 368 29671499
Hypotension 21.03 11.09 2166 278445 198399 29473468
Nausea 21.00 11.09 3129 277482 293828 29378039
Cytopenia 20.90 11.09 28 280583 8228 29663639
Renal oncocytoma 20.89 11.09 9 280602 27 29671840
Pancreatic carcinoma stage IV 20.88 11.09 13 280598 98 29671769
pH body fluid abnormal 20.80 11.09 8 280603 16 29671851
Drug use disorder 20.48 11.09 3 280608 3245 29668622
Clostridium difficile colitis 20.37 11.09 57 280554 12711 29659156
Staphylococcal bacteraemia 20.33 11.09 20 280591 6748 29665119
Metastases to liver 20.30 11.09 186 280425 11779 29660088
Pulmonary alveolar haemorrhage 20.29 11.09 19 280592 6562 29665305
Syncope 20.20 11.09 981 279630 83922 29587945
Amylase increased 20.15 11.09 108 280503 5733 29666134
End stage renal disease 20.09 11.09 24 280587 7411 29664456
Gangrene 19.97 11.09 91 280520 4523 29667344
Upper respiratory tract infection 19.95 11.09 163 280448 27313 29644554
Palmar-plantar erythrodysaesthesia syndrome 19.80 11.09 72 280539 14798 29657069
Haematocrit decreased 19.70 11.09 188 280423 30511 29641356
Pancreatic stent placement 19.60 11.09 8 280603 20 29671847
Genital candidiasis 19.56 11.09 11 280600 67 29671800
Electrocardiogram QT prolonged 19.52 11.09 228 280383 35607 29636260
Pulmonary embolism 19.47 11.09 570 280041 77565 29594302
Diffuse large B-cell lymphoma 19.44 11.09 27 280584 7814 29664053
Pleural effusion 19.29 11.09 537 280074 73529 29598338
Autoimmune pancreatitis 19.29 11.09 18 280593 262 29671605
Mucosal dryness 19.24 11.09 35 280576 1016 29670851
Foot amputation 19.23 11.09 23 280588 452 29671415
Disease recurrence 19.23 11.09 68 280543 14093 29657774
Liver disorder 19.08 11.09 182 280429 29540 29642327
Oxygen saturation decreased 19.07 11.09 289 280322 43151 29628716
Anaphylactic reaction 18.97 11.09 169 280442 27813 29644054
Leukoencephalopathy 18.75 11.09 7 280604 3995 29667872
Red blood cell count decreased 18.72 11.09 157 280454 26164 29645703
Hypoglycaemic unconsciousness 18.66 11.09 30 280581 786 29671081
Pneumonitis 18.53 11.09 166 280445 27288 29644579
Tenosynovitis 18.51 11.09 5 280606 3510 29668357
Cytomegalovirus chorioretinitis 18.48 11.09 4 280607 3264 29668603
Bladder cancer recurrent 18.45 11.09 19 280592 314 29671553
Glomerular filtration rate increased 18.42 11.09 16 280595 211 29671656
Birt-Hogg-Dube syndrome 18.40 11.09 5 280606 0 29671867
Product commingling 18.34 11.09 8 280603 25 29671842
Angioedema 18.13 11.09 436 280175 33948 29637919
Abdominal pain upper 18.01 11.09 737 279874 61814 29610053
Anion gap abnormal 17.96 11.09 13 280598 129 29671738
Herbal interaction 17.84 11.09 19 280592 327 29671540
Hyperventilation 17.82 11.09 57 280554 2392 29669475
Product complaint 17.81 11.09 104 280507 5702 29666165
Bacteraemia 17.78 11.09 80 280531 15480 29656387
Erythromelalgia 17.74 11.09 9 280602 43 29671824
Body mass index increased 17.71 11.09 27 280584 675 29671192
Needle issue 17.66 11.09 77 280534 3755 29668112
Aplasia pure red cell 17.64 11.09 16 280595 5610 29666257
Conjunctivitis 17.48 11.09 30 280581 7970 29663897
Dizziness 17.41 11.09 2083 278528 192826 29479041
Lacunar infarction 17.39 11.09 67 280544 3088 29668779
Hyperglycaemic hyperosmolar nonketotic syndrome 17.28 11.09 32 280579 942 29670925
Abdominal discomfort 17.20 11.09 588 280023 48203 29623664
Gastroenteritis 17.13 11.09 195 280416 13071 29658796
Atrioventricular block complete 17.13 11.09 137 280474 8340 29663527
Insulin-requiring type 2 diabetes mellitus 17.10 11.09 13 280598 140 29671727
Therapeutic drug monitoring analysis not performed 17.04 11.09 20 280591 385 29671482
Cystitis haemorrhagic 17.03 11.09 12 280599 4775 29667092
Peripheral vascular disorder 17.00 11.09 95 280516 5124 29666743
Atrioventricular block first degree 16.87 11.09 101 280510 5587 29666280
Blood ketone body present 16.81 11.09 9 280602 49 29671818
High density lipoprotein decreased 16.75 11.09 67 280544 3143 29668724
Neoplasm malignant 16.73 11.09 98 280513 17716 29654151
Crohn's disease 16.72 11.09 10 280601 4342 29667525
Erythema 16.65 11.09 576 280035 76875 29594992
Dysphagia 16.64 11.09 404 280207 56294 29615573
Torsade de pointes 16.61 11.09 26 280585 7164 29664703
Bradyarrhythmia 16.61 11.09 48 280563 1904 29669963
Hyperbilirubinaemia 16.56 11.09 92 280519 16850 29655017
Hyperdynamic left ventricle 16.54 11.09 10 280601 71 29671796
Diabetic foetopathy 16.49 11.09 15 280596 211 29671656
Hyperlipasaemia 16.48 11.09 22 280589 485 29671382
Coma scale abnormal 16.46 11.09 69 280542 3307 29668560
Fluid overload 16.39 11.09 108 280503 18984 29652883
Leukaemoid reaction 16.35 11.09 11 280600 96 29671771
Nipple inflammation 16.32 11.09 10 280601 73 29671794
Flushing 16.31 11.09 187 280424 29305 29642562
Fixed eruption 16.31 11.09 35 280576 1149 29670718
Neuropathy vitamin B12 deficiency 16.25 11.09 7 280604 21 29671846
Asthma 16.10 11.09 240 280371 35934 29635933
Complication associated with device 15.95 11.09 18 280593 5702 29666165
Hypovolaemic shock 15.95 11.09 110 280501 6390 29665477
Lithotripsy 15.93 11.09 6 280605 11 29671856
Plasmapheresis 15.85 11.09 18 280593 334 29671533
Multiple-drug resistance 15.84 11.09 4 280607 2937 29668930
Body temperature decreased 15.83 11.09 149 280462 9506 29662361
Cardiotoxicity 15.79 11.09 11 280600 4403 29667464
Clear cell renal cell carcinoma 15.78 11.09 30 280581 901 29670966
Prostatectomy 15.75 11.09 13 280598 159 29671708
Neonatal respiratory distress syndrome 15.72 11.09 9 280602 4003 29667864
Hepatojugular reflux 15.72 11.09 18 280593 337 29671530
Bronchitis 15.60 11.09 265 280346 38860 29633007
Generalised tonic-clonic seizure 15.60 11.09 113 280498 19438 29652429
Incorrect route of product administration 15.59 11.09 54 280557 11261 29660606
Intraductal papillary-mucinous carcinoma of pancreas 15.50 11.09 5 280606 4 29671863
Colitis ulcerative 15.44 11.09 76 280535 14358 29657509
Cardiac disorder 15.41 11.09 486 280125 39407 29632460
Fibrillary glomerulonephritis 15.32 11.09 8 280603 41 29671826
Sopor 15.31 11.09 164 280447 10827 29661040
Pseudomembranous colitis 15.25 11.09 4 280607 2864 29669003
Small intestinal obstruction 15.15 11.09 71 280540 13588 29658279
Blood alkaline phosphatase increased 15.04 11.09 206 280405 31281 29640586
Congestive cardiomyopathy 15.01 11.09 110 280501 6517 29665350
Pulmonary tuberculosis 15.00 11.09 14 280597 4843 29667024
Weight increased 14.88 11.09 851 279760 74062 29597805
Lymphoma 14.84 11.09 47 280564 10074 29661793
Rectal haemorrhage 14.80 11.09 234 280377 34705 29637162
Bladder papilloma 14.76 11.09 7 280604 28 29671839
Skinfold measurement 14.72 11.09 4 280607 0 29671867
Staphylococcal sepsis 14.68 11.09 43 280568 9448 29662419
Alopecia 14.62 11.09 113 280498 19162 29652705
Insulin C-peptide decreased 14.59 11.09 8 280603 46 29671821
Arthropathy 14.58 11.09 124 280487 20603 29651264
Bradycardia 14.52 11.09 752 279859 64774 29607093
Folliculitis 14.50 11.09 8 280603 3632 29668235
Status epilepticus 14.48 11.09 54 280557 11018 29660849
Virologic failure 14.47 11.09 6 280605 3213 29668654
Intraductal papillary mucinous neoplasm 14.44 11.09 10 280601 92 29671775
Leukocytosis 14.32 11.09 282 280329 21220 29650647
Lung disorder 14.28 11.09 208 280403 31261 29640606
Expired product administered 14.27 11.09 59 280552 2810 29669057
Multiple sclerosis relapse 14.19 11.09 53 280558 10809 29661058
Intercapillary glomerulosclerosis 14.19 11.09 8 280603 49 29671818
Patent ductus arteriosus 14.10 11.09 6 280605 3163 29668704
Injection site mass 14.09 11.09 87 280524 4866 29667001
Pancreatic duct obstruction 14.09 11.09 5 280606 7 29671860
Scrotal cyst 14.09 11.09 5 280606 7 29671860
Brain oedema 14.01 11.09 64 280547 12334 29659533
Akathisia 13.98 11.09 21 280590 5883 29665984
Urosepsis 13.97 11.09 158 280453 10574 29661293
Acid base balance abnormal 13.93 11.09 6 280605 18 29671849
Myasthenic syndrome 13.91 11.09 17 280594 342 29671525
Aplastic anaemia 13.91 11.09 19 280592 5537 29666330
Tongue disorder 13.90 11.09 12 280599 4310 29667557
Heparin-induced thrombocytopenia 13.89 11.09 18 280593 5365 29666502
Ischaemic stroke 13.89 11.09 222 280389 16053 29655814
Pneumatosis intestinalis 13.84 11.09 4 280607 2686 29669181
Eructation 13.83 11.09 67 280544 3417 29668450
Radiotherapy 13.82 11.09 18 280593 387 29671480
Mouth haemorrhage 13.76 11.09 16 280595 5001 29666866
Enthesopathy 13.75 11.09 5 280606 2901 29668966
Skin lesion 13.75 11.09 109 280502 18385 29653482
Blood albumin decreased 13.64 11.09 66 280545 12526 29659341
Blood calcium decreased 13.60 11.09 45 280566 9517 29662350
Renal artery thrombosis 13.59 11.09 16 280595 309 29671558
Graft versus host disease in skin 13.57 11.09 7 280604 3300 29668567
Labelled drug-disease interaction medication error 13.44 11.09 10 280601 104 29671763
Overweight 13.42 11.09 37 280574 1428 29670439
Hallucination, visual 13.40 11.09 92 280519 16021 29655846
Oscillopsia 13.39 11.09 7 280604 36 29671831
Cytomegalovirus colitis 13.27 11.09 3 280608 2376 29669491
Product appearance confusion 13.25 11.09 6 280605 21 29671846
Hypoparathyroidism 13.25 11.09 19 280592 449 29671418
Kussmaul respiration 13.20 11.09 10 280601 107 29671760
Thrombosis 13.20 11.09 298 280313 41933 29629934
Orbital oedema 13.17 11.09 11 280600 137 29671730
Ascites 13.15 11.09 247 280364 35674 29636193
Blood cholesterol 13.13 11.09 10 280601 108 29671759
Oesophageal perforation 13.09 11.09 19 280592 454 29671413
Pancreatectomy 13.09 11.09 7 280604 38 29671829
Thyroid cyst 13.04 11.09 6 280605 22 29671845
Conjunctival disorder 12.98 11.09 9 280602 83 29671784
Intentional self-injury 12.94 11.09 74 280537 13458 29658409
Gingival hypertrophy 12.80 11.09 39 280572 1594 29670273
Eosinophilic colitis 12.79 11.09 12 280599 176 29671691
Arthropod sting 12.79 11.09 14 280597 249 29671618
Hypersensitivity 12.74 11.09 397 280214 53631 29618236
Drug level below therapeutic 12.74 11.09 8 280603 3384 29668483
Dermatitis acneiform 12.74 11.09 21 280590 5668 29666199
Metastases to the mediastinum 12.73 11.09 12 280599 177 29671690
Thrombotic cerebral infarction 12.73 11.09 15 280596 290 29671577
Thyroxine abnormal 12.69 11.09 5 280606 11 29671856
Renal tubular disorder 12.65 11.09 17 280594 4989 29666878
Vascular graft 12.59 11.09 36 280575 1419 29670448
Bacterial infection 12.58 11.09 68 280543 12542 29659325
Respiratory syncytial virus infection 12.58 11.09 8 280603 3360 29668507
Influenza 12.52 11.09 310 280301 43088 29628779
Wheezing 12.51 11.09 209 280402 30729 29641138
Benign neoplasm of adrenal gland 12.51 11.09 4 280607 3 29671864
Hepatobiliary scan abnormal 12.51 11.09 4 280607 3 29671864
Penile abscess 12.51 11.09 4 280607 3 29671864
Brain herniation 12.50 11.09 10 280601 3730 29668137
Blindness cortical 12.49 11.09 15 280596 296 29671571
Viral infection 12.48 11.09 87 280524 15098 29656769
Finger amputation 12.47 11.09 12 280599 182 29671685
Full blood count decreased 12.46 11.09 91 280520 15626 29656241
Malnutrition 12.41 11.09 60 280551 11389 29660478
Coma acidotic 12.39 11.09 5 280606 12 29671855
Klebsiella infection 12.33 11.09 29 280582 6858 29665009
Explorative laparotomy 12.28 11.09 6 280605 26 29671841
Limb traumatic amputation 12.28 11.09 6 280605 26 29671841
Bundle branch block right 12.21 11.09 110 280501 6932 29664935
Hepatitis B 12.18 11.09 24 280587 6048 29665819
Vascular resistance systemic decreased 12.14 11.09 9 280602 93 29671774
Product solubility abnormal 12.12 11.09 20 280591 536 29671331
Peripheral sensory neuropathy 12.12 11.09 23 280588 5878 29665989
Blood pressure systolic increased 12.11 11.09 204 280407 14906 29656961
Myoclonus 12.09 11.09 74 280537 13238 29658629
Lichenification 12.08 11.09 15 280596 307 29671560
Nipple disorder 12.01 11.09 12 280599 191 29671676
Brain stem infarction 11.98 11.09 33 280578 1273 29670594
Type I hypersensitivity 11.90 11.09 27 280584 921 29670946
Enteritis 11.88 11.09 28 280583 6617 29665250
Cellulitis of male external genital organ 11.78 11.09 8 280603 71 29671796
Muscle spasticity 11.76 11.09 19 280592 5169 29666698
Neutrophilia 11.76 11.09 63 280548 3344 29668523
Pulmonary toxicity 11.76 11.09 15 280596 4501 29667366
Device issue 11.67 11.09 36 280575 7780 29664087
Inflammation 11.66 11.09 141 280470 21885 29649982
Post-traumatic amnestic disorder 11.66 11.09 7 280604 49 29671818
Hemiparaesthesia 11.66 11.09 7 280604 49 29671818
Subdural hygroma 11.64 11.09 15 280596 319 29671548
Vertigo 11.62 11.09 286 280325 22349 29649518
Metabolic syndrome 11.60 11.09 36 280575 1486 29670381
Carotid artery stenosis 11.56 11.09 79 280532 4575 29667292
Chronic pigmented purpura 11.54 11.09 9 280602 101 29671766
Hepatic neoplasm 11.52 11.09 41 280570 1818 29670049
Sedation 11.49 11.09 98 280513 16275 29655592
Squamous cell carcinoma of skin 11.48 11.09 45 280566 9050 29662817
Dyskinesia 11.47 11.09 140 280471 21694 29650173
Coma uraemic 11.44 11.09 7 280604 51 29671816
Acute respiratory distress syndrome 11.41 11.09 153 280458 23319 29648548
Medication error 11.38 11.09 267 280344 20705 29651162
Alcoholic ketoacidosis 11.37 11.09 5 280606 16 29671851
Prerenal failure 11.37 11.09 41 280570 1830 29670037
Hypoosmolar state 11.34 11.09 8 280603 76 29671791
Polymerase chain reaction 11.34 11.09 8 280603 76 29671791
Pyonephrosis 11.34 11.09 8 280603 76 29671791
Cholangiocarcinoma 11.32 11.09 27 280584 952 29670915
Choluria 11.32 11.09 11 280600 169 29671698
Lipodystrophy acquired 11.31 11.09 10 280601 3550 29668317
Hypoaesthesia eye 11.30 11.09 6 280605 32 29671835
Irritability 11.29 11.09 150 280461 22900 29648967
Mucormycosis 11.29 11.09 20 280591 5248 29666619
Venous occlusion 11.28 11.09 16 280595 374 29671493
Metabolic disorder 11.28 11.09 65 280546 3546 29668321
Stem cell transplant 11.28 11.09 3 280608 2128 29669739
Mouth ulceration 11.27 11.09 56 280555 10553 29661314
Drug ineffective for unapproved indication 11.23 11.09 58 280553 10822 29661045
Bacterial sepsis 11.20 11.09 18 280593 4908 29666959
Atrial fibrillation 11.20 11.09 1167 279444 106957 29564910
Hypogammaglobulinaemia 11.20 11.09 20 280591 5232 29666635
Toxic nodular goitre 11.15 11.09 5 280606 17 29671850
Pain in extremity 11.13 11.09 885 279726 109336 29562531
Lip oedema 11.12 11.09 46 280565 2191 29669676
Lipase abnormal 11.11 11.09 7 280604 54 29671813
Splenic varices 11.11 11.09 4 280607 6 29671861
Base excess negative 11.11 11.09 4 280607 6 29671861
Foetal malnutrition 11.11 11.09 7 280604 54 29671813
Dumping syndrome 11.11 11.09 4 280607 6 29671861
Drug screen positive 11.10 11.09 15 280596 4392 29667475

Pharmacologic Action:

SourceCodeDescription
ATC A10BA02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Biguanides
ATC A10BD02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD03 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD05 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD07 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD08 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD10 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD11 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD13 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD14 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD15 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD16 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD17 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD18 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD20 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD22 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD23 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD25 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD26 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
FDA CS M0002471 Biguanides
FDA EPC N0000175565 Biguanide
CHEBI has role CHEBI:35526 hypoglycemic drug
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:78298 environmental contaminants
MeSH PA D007004 Hypoglycemic Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Treatment Refractory Type 2 Diabetes Mellitus indication
Gestational diabetes mellitus off-label use 11687002 DOID:11714
Polycystic ovaries off-label use 69878008
Weight loss off-label use 89362005
Polycystic ovary syndrome off-label use 237055002 DOID:11612
Prevention of Type 2 Diabetes Mellitus off-label use
Alcoholism contraindication 7200002
Weight gain finding contraindication 8943002
Asthenia contraindication 13791008
Pulmonary edema contraindication 19242006 DOID:11396
Myocardial infarction contraindication 22298006 DOID:5844
Acute vomiting contraindication 23971007
Severe adrenal insufficiency contraindication 24867002
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Dehydration contraindication 34095006
Macular retinal edema contraindication 37231002 DOID:4449
Infectious disease contraindication 40733004
Body fluid retention contraindication 43498006
End stage renal disease contraindication 46177005 DOID:784
Chronic heart failure contraindication 48447003
Lymphocytopenia contraindication 48813009 DOID:614
Hepatic porphyria contraindication 55056006 DOID:3133
Ketoacidosis contraindication 56051008
Acute nephropathy contraindication 58574008
Metabolic acidosis contraindication 59455009
Hepatic failure contraindication 59927004
Hemolytic anemia contraindication 61261009 DOID:583
Glucose-6-phosphate dehydrogenase deficiency anemia contraindication 62403005
Acute infectious disease contraindication 63171007
Osteoporosis contraindication 64859006 DOID:11476
Hypopituitarism contraindication 74728003 DOID:9406
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Fracture of bone contraindication 125605004
Liver function tests abnormal contraindication 166603001
Cobalamin deficiency contraindication 190634004
Angina pectoris contraindication 194828000
Decompensated cardiac failure contraindication 195111005
Acute pancreatitis contraindication 197456007 DOID:2913
Impaired renal function disorder contraindication 197663003
Cerebrovascular accident contraindication 230690007
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Hypoglycemic disorder contraindication 237630007
Sepsis syndrome contraindication 238150007
Edema contraindication 267038008
Osteopenia contraindication 312894000
Primary adrenocortical insufficiency contraindication 373662000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Fever contraindication 386661006
Surgical procedure contraindication 387713003
Malignant tumor of urinary bladder contraindication 399326009 DOID:11054
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Traumatic injury contraindication 417746004
Fever greater than 100.4 Fahrenheit contraindication 426000000
Severe Hypoxemia contraindication
Prolonged-Severe Nausea and Vomiting contraindication
Radiography with IV Iodinated Contrast Agent contraindication
Severe Autonomic Insufficiency contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.63 Basic
pKa2 3.34 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL Oct. 29, 2021 NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL Oct. 29, 2021 NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL Oct. 29, 2021 NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL Oct. 29, 2021 NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL Oct. 29, 2021 NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL Oct. 29, 2021 NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL Oct. 29, 2021 NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL Oct. 29, 2021 NEW INDICATION FOR CANULLGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)
10MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL May 2, 2022 NEW PRODUCT
2.5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL May 2, 2022 NEW PRODUCT
5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL May 2, 2022 NEW PRODUCT
5MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL May 2, 2022 NEW PRODUCT
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL July 3, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINULL TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL July 3, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINULL TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL July 3, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINULL TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL July 3, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINULL TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL July 3, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINULL TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Aug. 12, 2022 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Aug. 12, 2022 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
1GM;EQ 100MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Aug. 12, 2022 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Aug. 12, 2022 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Aug. 12, 2022 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Oct. 18, 2022 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Oct. 18, 2022 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL Oct. 18, 2022 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Oct. 18, 2022 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Oct. 18, 2022 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
2.5MG;1GM SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
2.5MG;500MG SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
7.5MG;1GM SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
7.5MG;500MG SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
1GM;EQ 100MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Dec. 4, 2023 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Dec. 4, 2023 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Dec. 4, 2023 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Dec. 4, 2023 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL June 4, 2024 PEDIATRIC EXCLUSIVITY
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL June 4, 2024 PEDIATRIC EXCLUSIVITY
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL June 4, 2024 PEDIATRIC EXCLUSIVITY
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL June 4, 2024 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mitochondrial complex I (NADH dehydrogenase) Enzyme INHIBITOR CHEMBL CHEMBL
Dipeptidyl peptidase 4 Enzyme IC50 4.54 CHEMBL
5'-AMP-activated protein kinase subunit beta-1 Kinase WOMBAT-PK
Solute carrier family 22 member 3 Transporter Km 2.50 WOMBAT-PK
Solute carrier family 22 member 2 Transporter IC50 3.40 WOMBAT-PK
Solute carrier family 22 member 1 Transporter IC50 2.70 WOMBAT-PK

External reference:

IDSource
4023979 VUID
N0000021984 NUI
D00944 KEGG_DRUG
1115-70-4 SECONDARY_CAS_RN
4020898 VANDF
4023979 VANDF
C0591573 UMLSCUI
CHEBI:6802 CHEBI
MF8 PDB_CHEM_ID
CHEMBL1703 ChEMBL_ID
CHEMBL1431 ChEMBL_ID
D008687 MESH_DESCRIPTOR_UI
DB00331 DRUGBANK_ID
4779 IUPHAR_LIGAND_ID
965 INN_ID
9100L32L2N UNII
14219 PUBCHEM_CID
151827 RXNORM
41717 MMSL
5063 MMSL
592 MMSL
d03807 MMSL
003483 NDDF
004534 NDDF
109081006 SNOMEDCT_US
109083009 SNOMEDCT_US
372567009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0078 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 31 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0080 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 31 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0081 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 31 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0575 TABLET, FILM COATED 500 mg ORAL NDA 30 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0577 TABLET, FILM COATED 1000 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5369 TABLET, FILM COATED 500 mg ORAL NDA 29 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5370 TABLET, FILM COATED 500 mg ORAL NDA 29 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5373 TABLET, FILM COATED 1000 mg ORAL NDA 29 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5374 TABLET, FILM COATED 1000 mg ORAL NDA 29 sections
GLUCOPHAGE HUMAN PRESCRIPTION DRUG LABEL 1 0087-6060 TABLET, FILM COATED 500 mg ORAL NDA 18 sections
GLUCOPHAGEXR HUMAN PRESCRIPTION DRUG LABEL 1 0087-6063 TABLET, EXTENDED RELEASE 500 mg ORAL NDA 18 sections
GLUCOPHAGEXR HUMAN PRESCRIPTION DRUG LABEL 1 0087-6064 TABLET, EXTENDED RELEASE 750 mg ORAL NDA 18 sections
GLUCOPHAGE HUMAN PRESCRIPTION DRUG LABEL 1 0087-6070 TABLET, FILM COATED 850 mg ORAL NDA 18 sections
GLUCOPHAGE HUMAN PRESCRIPTION DRUG LABEL 1 0087-6071 TABLET, FILM COATED 1000 mg ORAL NDA 18 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7455 TABLET, FILM COATED 250 mg ORAL ANDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7456 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7457 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
metformin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-4416 TABLET, EXTENDED RELEASE 500 mg ORAL ANDA 28 sections
Glyburide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0228-2751 TABLET, FILM COATED 250 mg ORAL ANDA 27 sections
Glyburide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0228-2752 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
Glyburide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0228-2753 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
KOMBIGLYZEXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6125 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
KOMBIGLYZEXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6135 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 30 sections
KOMBIGLYZEXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6145 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6225 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6250 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 30 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6260 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6270 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 30 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6280 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-6001 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL ANDA 29 sections